Biotest AG — Board/Management Information 2005

May 20, 2005

News Details

Corporate | 20 May 2005 14:51

Biotest AG: Dr. Thorlef Spickschen new Chairman of the Supervisory Board

Corporate-news transmitted by DGAP. The issuer is solely responsible for the content of this announcement. —————————————————————————— Biotest AG: Dr. Thorlef Spickschen new Chairman of the Supervisory Board Dreieich, May 20, 2005. Today’s General Meeting elected Dr. Thorlef Spickschen to Biotest AG’s Supervisory Board as a shareholder representative. After the meeting, the Supervisory Board elected the 64-year old business administration graduate as its Chairman. The former Chairman, Werner Spinner, resigned from office as of the end of the General Meeting as he regards his tasks as having been completed now that the company’s restructuring has been successfully concluded. Like his predecessor Thorlef Spickschen also has many years of experience in the pharmaceutical sector. He previously held management positions with Eli Lilly and Boehringer Mannheim, and was then Chairman of the Managing Board with Knoll AG, which at that time belonged to BASF. He is now a member of the supervisory boards and advisory councils of several international pharmaceutical and biotechnology companies. This ensures that the successful activities of Werner Spinner can be continued in a highly consistent manner. The Deputy Chairman of the Supervisory Board, Dr. Cathrin Schleussner, thanked Mr. Spinner for his commitment, which made a major contribution to rectifying the crisis-ridden situation. Biotest AG’s shareholders also approved the additional proposed resolutions with a large majority. The appropriation of net profits and the disbursement of a dividend of EUR 0.11 for both preferred and, for the first time again for ordinary shares, was approved now that the company has returned to the profit zone after recording net income of EUR 5.0 million last financial year. The proposed expansion of the authorization to increase capital was also approved. This allows the Board of Management and Supervisory Board to accelerate the highly promising development of monoclonal antibodies with new equity. Investor Relations: Hubert Bötsch, Telephone: +49 (0) 6103 801-444, Telefax: +49(0)6103/801-880, E-mail: hubert_boetsch@biotest.de Biotest AG, Landsteinerstrasse 5, 63303 Dreieich, Germany WKN (German Securities Code), ISIN ordinary shares: 522720, DE0005227201 WKN (German Securities Code), ISIN preferred shares: 522723, DE0005227235 Listed: Prime Standard/ Amtlicher Handel (Official Trading) Frankfurt, Berlin, Düsseldorf, Hamburg, Stuttgart End of announcement (c)DGAP 20.05.2005 —————————————————————————— WKN: 522720; ISIN: DE0005227201; Index: Listed: Amtlicher Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin- Bremen, Düsseldorf, Hamburg und Stuttgart 201451 Mai 05